JP2012527867A5 - - Google Patents

Download PDF

Info

Publication number
JP2012527867A5
JP2012527867A5 JP2011550339A JP2011550339A JP2012527867A5 JP 2012527867 A5 JP2012527867 A5 JP 2012527867A5 JP 2011550339 A JP2011550339 A JP 2011550339A JP 2011550339 A JP2011550339 A JP 2011550339A JP 2012527867 A5 JP2012527867 A5 JP 2012527867A5
Authority
JP
Japan
Prior art keywords
peptide
group
amino acid
apc
ctl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011550339A
Other languages
English (en)
Japanese (ja)
Other versions
JP5903697B2 (ja
JP2012527867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2010/003488 external-priority patent/WO2010137295A1/en
Publication of JP2012527867A publication Critical patent/JP2012527867A/ja
Publication of JP2012527867A5 publication Critical patent/JP2012527867A5/ja
Application granted granted Critical
Publication of JP5903697B2 publication Critical patent/JP5903697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011550339A 2009-05-26 2010-05-25 Cdc45lペプチドおよびそれを含むワクチン Active JP5903697B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21713309P 2009-05-26 2009-05-26
US61/217,133 2009-05-26
PCT/JP2010/003488 WO2010137295A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Publications (3)

Publication Number Publication Date
JP2012527867A JP2012527867A (ja) 2012-11-12
JP2012527867A5 true JP2012527867A5 (enExample) 2013-07-11
JP5903697B2 JP5903697B2 (ja) 2016-04-20

Family

ID=43222423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550339A Active JP5903697B2 (ja) 2009-05-26 2010-05-25 Cdc45lペプチドおよびそれを含むワクチン

Country Status (16)

Country Link
US (1) US8586547B2 (enExample)
EP (4) EP3208334B1 (enExample)
JP (1) JP5903697B2 (enExample)
KR (1) KR101765452B1 (enExample)
CN (3) CN103694315B (enExample)
AU (1) AU2010253356B2 (enExample)
BR (1) BRPI1010666B1 (enExample)
CA (3) CA3167451A1 (enExample)
DK (3) DK2435567T3 (enExample)
ES (3) ES2631952T3 (enExample)
IL (1) IL216211A (enExample)
MX (1) MX2011012619A (enExample)
RU (1) RU2562160C2 (enExample)
SG (1) SG176058A1 (enExample)
TW (1) TWI507204B (enExample)
WO (1) WO2010137295A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2633503C2 (ru) 2011-10-28 2017-10-12 Онкотерапи Сайенс, Инк. Пептиды торк и содержащие их вакцины
EP3202783A1 (en) 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
ES2913268T3 (es) 2017-01-25 2022-06-01 Ose Immunotherapeutics Método para fabricar una emulsión estable para la administración de péptidos
JP7281774B2 (ja) 2017-09-19 2023-05-26 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 抗hla-a2抗体及びその使用方法
CA3076547A1 (en) 2017-09-20 2019-03-28 The University Of British Columbia Novel anti-hla-a2 antibodies and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US20030083461A1 (en) * 1997-06-16 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
ES2294844T3 (es) 1998-06-25 2008-04-01 Green Peptide Co., Ltd. Peptidos antigenicos tumorales derivados de ciclofilina b.
CA2440773A1 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
CN103073620B (zh) * 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP4370409B2 (ja) 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
WO2007013665A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 T細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
US8470534B2 (en) 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Foxp3胜肽疫苗

Similar Documents

Publication Publication Date Title
JP2012500001A5 (enExample)
JP2012517799A5 (enExample)
JP2011524737A5 (enExample)
JP2010523471A5 (enExample)
HRP20141233T1 (hr) PEPTIDNA CJEPIVA DOBIVENA IZ EphA4
JP2010506826A5 (enExample)
RU2011110504A (ru) Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды
RU2009141595A (ru) Пептиды тем8 и содержащие их вакцины
RU2011138160A (ru) Пептиды foxmi и вакцины, содержащие их
JP2016511221A5 (enExample)
JP2008530975A5 (enExample)
JP2013511958A5 (enExample)
RU2012127358A (ru) Олигопептиды imp-3 и содержащие их вакцины
JP2013523084A5 (enExample)
JP2011522777A5 (enExample)
JP2015529219A5 (enExample)
JP2012520659A5 (enExample)
JP2013517764A5 (enExample)
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
JP2012527867A5 (enExample)
JP2014533095A5 (enExample)
RU2014121502A (ru) Пептиды торк и содержащие их вакцины
JP2014519311A5 (enExample)
JP2011529683A5 (enExample)
RU2013158399A (ru) Пептиды sema5b и содержащие их вакцины